Fig. 1 · Structure

Documents & Downloads

Nelfinavir

Cat. No. A11504 CAS 159989-64-7

HIV-1 protease inhibitor

Nelfinavir is a potent and orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (Ki=2 nM) and is widely prescribed in combination with HIV reverse transcriptase inhibitors for the treatment of HIV infection.

In Stock

Publications for Nelfinavir

3 publications citing this product

  1. Joanna Ireland, .et al. , Front Microbiol, 2024, Mar 20:15:1385775 PMID: 38572241
  2. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  3. Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HIV-1  

Cellular Effect

Cell Line Activity Value Description Reference
CCRF-CEM EC50 100 nM Antiviral activity against HIV2 ROD with protease G17N/V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay [PMID: 17576848]
CCRF-CEM EC50 177 nM Antiviral activity against HIV2 ROD with protease V47A mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay [PMID: 17576848]
CCRF-CEM EC50 199 nM Antiviral activity against HIV2 ROD with protease G17N mutation infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay [PMID: 17576848]
CCRF-CEM EC50 281 nM Antiviral activity against wild type HIV2 ROD infected in human CEM cells assessed as inhibition of virus production after 7 days by Lenti-RT activity assay [PMID: 17576848]
CEM-SS ED50 0.03 μM Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay [PMID: 15217281]
CEM-SS IC50 2 nM Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as reverse transcriptase activity after 5 days by MTT assay [PMID: 17950955]
HEK293 EC50 5.8 nM Antiviral activity against wild type HIV1 NL4-3 in HEK293 cells after 48 hrs by replication-deffective luciferase reporter gene-based phenotypic assay [PMID: 17638694]
HeLa EC50 > 1 μM Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay [PMID: 19805571]
HeLa EC50 > 1 μM Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay [PMID: 17646410]
HeLa EC50 > 1 μM Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay [PMID: 17646410]
HeLa EC50 0.013 μM Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay [PMID: 19805571]
HeLa EC50 0.016 μM Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay [PMID: 19805571]
HeLa EC50 0.038 μM Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay [PMID: 19805571]
HepG2 CC50 7.4 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 5 days by XTT assay 10.1039/C1MD00147G
LLC-PK1 IC50 2.3 μM Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay [PMID: 12699389]
LLC-PK1 IC50 3.4 μM Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay [PMID: 12699389]
MOLT-4 EC50 0.029 μM Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay [PMID: 18316521]
MT2 EC50 0.023 μM Antiviral activity against HIV1 LAI infected in human MT2 cells after 7 days by MTT assay [PMID: 18955518]

18 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 159989-64-7
Applications HIV-1 protease inhibitor
Formula C32H45N3O4S
Molecular Weight 567.78
Synonyms Viracept; AG 1341
SMILES
CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Publications

3 publications citing this product

  1. Joanna Ireland, .et al. , Front Microbiol, 2024, Mar 20:15:1385775 PMID: 38572241
  2. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  3. Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078

Added to your cart

View Cart Checkout
Loading...